Graft-vs-Host Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we wanted to determine if very low doses of Tregs generated using the "2-pathway" stimulation protocol via TL1A-Ig fusion protein and low-dose IL-2 (targeting TNFRSF25 and CD25, respectively) could be used to regulate preclinical GVHD.
|
29751114 |
2018 |
Graft-vs-Host Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of checkpoint blockade molecules PD-1, PD-L1, CTLA-4, and foxp3+CD25+CD4+ T cells (Tregs) regulate donor T cell activation and graft-vs-host disease (GvHD) in allogeneic hematopoietic stem cell transplant (allo-HSCT).
|
28953925 |
2017 |
Graft-vs-Host Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Freeze and Thaw of CD4+CD25+Foxp3+ Regulatory T Cells Results in Loss of CD62L Expression and a Reduced Capacity to Protect against Graft-versus-Host Disease.
|
26693907 |
2015 |
Graft-vs-Host Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
For this purpose, adoptively transferred CD4+CD25+ Tregs from gzmA-/- mice were analyzed in comparison to their wild type counterparts for their capability to prevent murine GvHD.
|
25928296 |
2015 |
Graft-vs-Host Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, CD25(+)Foxp3(+) Tregs of Fanca(-/-) or Fancd2(-/-) mice were less efficient in suppressing the production of GVHD-associated inflammatory cytokines.
|
24501220 |
2014 |
Graft-vs-Host Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our and other laboratories have shown that the transfer of highly purified CD4(+)CD25(+)Foxp3(+) natural Treg can prevent lethal graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation across both major and minor histocompatibility barriers.
|
23921175 |
2013 |
Graft-vs-Host Disease
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Correlation of the CD4+CD25high T-regulatory cells in recipients and their corresponding donors to acute GVHD.
|
17313446 |
2007 |
Graft-vs-Host Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together these findings suggest that FOXP3-mRNA expression primarily reflects CD4(+)CD25+ cell frequency rather than defining the regulatory potential of CD4(+)CD25+ T cells and GvHD risk after HSCT.
|
16585024 |
2006 |
Graft-vs-Host Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In murine transplantation models, administration of naturally occurring CD4+CD25+ regulatory T cells (Treg) can prevent GvHD.
|
17000688 |
2006 |
Graft-vs-Host Disease
|
0.100 |
Biomarker
|
disease |
LHGDN |
Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.
|
15972448 |
2005 |
Graft-vs-Host Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD25-expressing donor T cells may be involved in the prevention or induction of GvHD as these cells comprise both CD4 +CD25+ regulatory T (Treg) cells and preactivated CD4+ or CD8+ conventional T cells.
|
16219576 |
2005 |
Graft-vs-Host Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, levels of Foxp3 mRNA in the CD25+ T-cell compartment do not allow predicting the development of GvHD in the long term.
|
16038781 |
2005 |
Graft-vs-Host Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacological immunosuppression for GVHD prophylaxis and therapy, including unspecific approaches with corticosteroids or methotrexate (MTX), as well as more specific therapy with cyclosporin A (CsA), tacrolimus (FK506), sirolimus, mycophenolate mofetil (MMF), antithymocyte globulin (ATG), and monoclonal antibodies (MAbs) directed against CD3, CD25, CD52, cytotoxic T-lymphocyte antigen (CTLA)-4, CD40 ligand, or TNF-alpha, have been proven to be effective.
|
15449032 |
2004 |
Graft-vs-Host Disease
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Similarity between eruptions induced by sulfhydryl drugs and acute cutaneous graft-versus-host disease after bone marrow transplantation.
|
12171778 |
2002 |